Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: Initial and long term results - Eastern Cooperative Oncology Group study E2878

Cancer

Volumn 77, Issue 4, 1996, Pages 733-742

  Wadler, Scott ^a,d   Yeap, Beow ^b   Vogl, Steven ^a   Carbone, Paul ^c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

^d MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

Borderline tumor; Cisplatin; Melphalan; Ovarian carcinoma; Ovary

Indexed keywords

ALKYLATING AGENT; ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; MELPHALAN;

ADULT; ADVANCED CANCER; ANAPHYLAXIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; FEMALE; GASTROINTESTINAL HEMORRHAGE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; NEUTROPENIA; ORAL DRUG ADMINISTRATION; OVARY CARCINOMA; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT FAILURE;

ADULT; AGED; ALTRETAMINE; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; CISPLATIN; CROSS-OVER STUDIES; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; OVARIAN NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 0030041332     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960215)77:4<733::AID-CNCR20>3.0.CO;2-0     Document Type: Article

References (25)

1. Boring CC, Squires TS, Tong T. Cancer statistics, 1993. CA Cancer J Clin 1993;43:7-27.
2. Advanced Ovarian Cancer Trialists Group. Chemotherapy in advanced ovarian cancer: an overview of randomised clinical trials. BMJ 1991;303:884-93.
3. Young RC, Chabner BA, Hubbard SP, Fisher RI, Bender RA, Anderson T, et al. Advanced ovarian adenocarcinoma: a prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med 1978;299:1261-6.
4. Ozols RF, Garrin AJ, Costa J, Simon RM, Young RC. Advanced ovarian cancer: correlations of histologic grade with response to therapy and survival. Cancer 1980;45:572-81.
5. Neijt JP. Treatment of advanced ovarian cancer: 10 years of experience. Ann Oncol 1992;3:17-27.
6. Vogl SE, Greenwald E, Kaplan BH, Moukhtar M, Wollner D. Ovarian cancer. Effective treatment after alkylating agent failure. JAMA 1979;241:1908-11.
7. Vogl SE, Berenzweig M, Kaplan BH, Moukhtar M, Bulkin W. The CHAD and HAD regimens in advanced ovarian cancer: combination chemotherapy including cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum (II). Cancer Treat Rep 1979;63:311-17.
8. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55.
9. Cox DR, Snell EJ. Analysis of binary data. 2nd edition. London: Chapman and Hall, 1989.
10. Armitage P. Test for linear trend proportions and frequencies. Biometrics 1955;11:375-86.
11. Kaplan EL, Meier P. Non-parametric estimation of incomplete observations. J Am Stat Assoc 1958;53:457-81.
12. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
13. Cox DR. Regression models and life tables. J R Stat Soc Series B 1972;34:187-220.
14. Sviland L, Robinson A, Proctor SJ, Bateman DV. Interaction of cimetidine with oral melphalan. A pharmacokinetic study. Cancer Chemother Pharmacol 1987;20:173-5.
15. Grossman MI, Kirsner JB, Gillespie IE. Basal and histalogstimulated gastric secretion in control subjects and in patients with peptic ulcer or gastric ulcer. Gastroenterology 1963;45:14-8.
16. Decker DG, Fleming TR, Malkasian GD, Webb MJ, Jefferies JA, Edmonson HJ. Cyclophosphamide plus cisplatinum in combination: treatment programs for stage III or IV ovarian carcinoma. Obstet Gynecol 1982;60:481-7.
17. Bell DR, Woods RL, Levi JA, Fox RM, Tattersall MHN. Advanced ovarian cancer: a prospective randomized trial of chlorambucil versus combined cyclophosphamide and cis-diamminedichloroplatinum. Aust NZJ Med 1982;12: 245-9.
18. Omura GA, Brady MF, Homesley HD, Yordan E, Major FJ, Buchsbaum HJ, et al. Long term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol 1991;9:1138-50.
19. Levi F, Franceschi S, La Vecchia C, Ruzicka J, Gloor E, Randimbison. I. Epidemiologic pathology of ovarian cancer from the Vaud Cancer Registry, Switzerland. Ann Oncol 1993;4: 289-94.
20. Sturgeon JFG, Fine S, Gospodarowicz MK, Dembo AJ, Bean HA, Bush RS, et al. A randomized trial of melphalan alone versus combination chemotherapy in advanced ovarian cancer. Proc Am Soc Clin Oncol 1982;1:108.
21. Neijet JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Vriesendorp R, Kooyman CD, et al. Randomized trial comparing two combination chemotherapy regimens (HexaCAF v CHAP-5) in advanced ovarian carcinoma. Lancet 1984;II:594-600.
22. Neijet JP, ten Bokkel Huinink WW, van der Burg ME, van Oosterom AT, Willemse PH, Heintz, AP, et al. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma. J Clin Oncol 1987;5:1157-68.
23. Sessa C, Colombo N, Bolis G, Marsoni S, Mangioni C. Randomized comparison of hexamethylmelamine, Adriamycin, cyclophosphamide (HAC) vs cisplatin, Adriamycin, cyclophosphamide (PAC) in advanced ovarian cancer: long-term results. Cancer Treat Rev 1991;18(Suppl A):37-46.
24. A'Hern RP, Gore ME. Impact of doxorubicin on survival in advanced ovarian cancer. J Clin Oncol 1995;13:726-32.
25. Wiernik PH, Yeap B, Vogl S, Kaplan BH, Comis RL, Falkson G, et al. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest 1992a;10:1-9.